RxDoctor Payments Data

Archana Vasudevan, MD

Infectious Disease · Morgantown, WVNPI 1194130088

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,187 of the $1,392 with a category attached, or 85.3%. It is spread thinly across 17 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among infectious disease clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,392in general payments, 2019–2025

Across 68 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$190
  • Insmed, Inc.$188
  • Cumberland Pharmaceuticals, Inc.$168
  • Astellas Pharma US Inc$157
  • Merck$120
  • AbbVie$102
  • plus $467 from 11 others

What the payments were for

  • Food & beverage$1,18785%
  • Education$20515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,392 in reported general payments places this provider in the 90th percentile of 39 infectious disease providers in West Virginia.

See all infectious disease providers in West Virginia

Medicare billing

Part B allowed, 2024
$49,616
Medicare patients
190
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala25$115,613
Daptomycin17$38,593
ErtapenemErtapenem Sodium11$11,299
CeftriaxoneCeftriaxone Sodium11$594
Entecavir12$547
Doxycycline Hyclate41$469
Cephalexin27$403
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$387
Amoxicillin23$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$190$115,61325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 infectious disease providers in West Virginia.

Other infectious disease in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →